ニュース
ニュース
Holy Stone Healthcare Co., Ltd. and Professor Lior Rosenberg, co-founder of MediWound, jointly participated in the 2023 Taiwan Society for Burn Injuries and Wound Healing Annual Conference
05, Sep 2023
The Taiwan Society for Burn Injuries and Wound Healing Annual Conference and Academic Symposium took place from September 2nd to September 3rd, 2023, at the Chung Shan Medical University Hospital. This year, Holy Stone Healthcare Co., Ltd. (4194.TW) (Holy Stone) invited Professor Lior Rosenberg, co-founder of MediWound, to visit Taiwan and participate in this annual conference.
At the conference, Holy Stone showcased and introduced the innovative drug NexoBrid®, to the attending burn and wound care experts and nursing professionals from Taiwan. Professor Lior Rosenberg, co-founder of MediWound, delivered two lectures during the conference, sharing relevant research and clinical experiences regarding the use of NexoBrid® in patient treatment and burn wound care. The two lecture topics were "Enzymatic debridement of burns: The NexoBrid Minimal Invasive Modality paradigm change" and "The practice of NexoBrid use: Do and Don't Do," which attracted a large audience of burn and wound care experts and medical personnel.
NexoBrid® is a drug for which Holy Stone signed an exclusive distribution agreement with the Israeli drug development company MediWound Ltd (Nasdaq: MDWD) in 2017. This drug is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns. NexoBrid® represents a selective and minimally invasive modality - termed enzymatic debridement therapy, to replace the highly invasive surgical debridement which is used in the current Stand of Care (SOC).
Through this annual conference and academic symposium, Holy Stone provided burn and wound care experts a deeper understanding of the applications of the new drug. Additionally, by direct face-to-face communication between Professor Rosenberg and Taiwanese burn and wound care experts, Holy Stone aims to encourage and facilitate the adoption of NexoBrid® in burn care centers across Taiwan. This would provide burn and wound patients with a groundbreaking enzymatic debridement therapy, improving the care and treatment quality of burn injuries.
For further reading (In Chinese):
MediWound Co-founder Appears to Share Insights into Taiwan-Israel Collaboration on the World's First Pineapple Enzyme Debridement Drug.
At the conference, Holy Stone showcased and introduced the innovative drug NexoBrid®, to the attending burn and wound care experts and nursing professionals from Taiwan. Professor Lior Rosenberg, co-founder of MediWound, delivered two lectures during the conference, sharing relevant research and clinical experiences regarding the use of NexoBrid® in patient treatment and burn wound care. The two lecture topics were "Enzymatic debridement of burns: The NexoBrid Minimal Invasive Modality paradigm change" and "The practice of NexoBrid use: Do and Don't Do," which attracted a large audience of burn and wound care experts and medical personnel.
NexoBrid® is a drug for which Holy Stone signed an exclusive distribution agreement with the Israeli drug development company MediWound Ltd (Nasdaq: MDWD) in 2017. This drug is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns. NexoBrid® represents a selective and minimally invasive modality - termed enzymatic debridement therapy, to replace the highly invasive surgical debridement which is used in the current Stand of Care (SOC).
Through this annual conference and academic symposium, Holy Stone provided burn and wound care experts a deeper understanding of the applications of the new drug. Additionally, by direct face-to-face communication between Professor Rosenberg and Taiwanese burn and wound care experts, Holy Stone aims to encourage and facilitate the adoption of NexoBrid® in burn care centers across Taiwan. This would provide burn and wound patients with a groundbreaking enzymatic debridement therapy, improving the care and treatment quality of burn injuries.
For further reading (In Chinese):
MediWound Co-founder Appears to Share Insights into Taiwan-Israel Collaboration on the World's First Pineapple Enzyme Debridement Drug.